Geneva, Jan. 12 -- International Clinical Trials Registry received information related to the study (ChiCTR2500115104) titled 'Bendamustine combined with Zuberitamab (BZ) followed by Orelabrutinib combined with Zuberitamab (OZ) in the treatment of newly diagnosed marginal zone lymphoma:A Phase II prospective clinical study' on Dec. 22, 2025.
Study Type: Interventional study
Study Design:
Single arm
Primary Sponsor: The First Affiliated Hospital of the Air Force Medical University
Condition:
Marginal Zone Lymphoma
Recruitment Status: Not Recruiting
Phase: N/A
Date of First Enrollment: 2025-12-22
Target Sample Size: Treatment group:74;
Countries of Recruitment:
China
To know more, visit https://www.chictr.org.cn/showproj.htm...